Biology subjects

Scheller, L.

Publications and source records attributed to Scheller, L..

9 recordsLinked to original sources

bioRxiv2025

Rational design of chemically responsive cytokines for cancer immunotherapy

Cytokines are key signal mediators of the immune system, playing essential roles in regulating central immunological processes. Despite their unique ability to modulate the immune system, the translation of cytokine-based therapies to the clinic has been significantly hindered by severe toxicities resulting from the pleiotropy and off-target effects of many cytokines. Here, we present a general strategy for the design of switchable cytokines that enables precise control over cytokine activity using the clinically approved drug, Venetoclax. We rationally designed self-inhibited Switchable InterLeukins (SwILs) by embedding the chemically controlled interface (Bcl-2: BIM-BH3) into the cytokines structure, resulting in conditional cytokines activated by Venetoclax. We showed the broad applicability of this strategy across various cytokines, including IL-2, IL-15, and IL-10. In vivo studies with IL-15 demonstrated that the SwILs achieved Venetoclax-dependent tumor control comparable to that of the native cytokine. Additionally, we showed that this strategy can be expanded to respond to other tumor-intrinsic stimuli, such as tumor-specific proteases. Overall, SwILs offer control of cytokine activity, enhancing the safety and clinical applicability of cytokine-based therapeutics.

bioengineering↗

bioRxiv2025

De novo design of phosphorylation-induced protein switches for synthetic signaling in cells

A hallmark of living systems is their ability to respond and adapt to many types of exogenous and endogenous cues. At the core of this capability lie the evolved mechanisms of cellular signaling which perform the relay of biochemical signals throughout the cell. Much of this core signaling functionality in living systems is afforded by the ability of proteins to change their chemical and structural "status", by populating distinct states in conformational landscapes, undergoing post-translational modifications that alter these populations, and dynamically interacting with other cellular partners. Despite the remarkable advances we have witnessed in computational protein design, it remains an outstanding challenge to rationally design many of these aspects that are at the core of biological function. Here, we set out to design a minimal signaling network triggered by phosphorylation, which relies on de novo components that sample low-populated conformational states to control a designed protein interaction. In these designed components we implemented principles of signal amplification, conformational heterogeneity and molecular recognition which are ubiquitously used by nature to sustain biological function in cells. The designed proteins were biochemically and structurally characterized and ultimately are functional in cell-based systems where they regulate the transcription of reporter proteins in a phosphorylation-dependent manner. Overall, this work lays the foundation for designing synthetic signaling cascades using de novo protein components, which could be important to enhance our understanding of natural systems and for relevant applications in synthetic biology.

bioengineering↗

bioRxiv2025

Humanized Caffeine-Inducible Systems for Controlling Cellular Functions

Current cell therapies are limited by the lack of tools for controlling gene expression using humanized systems responsive to non-toxic stimuli. Starting from nanobodies that homodimerize in response to caffeine, we computationally designed inducible heterodimers and humanized the best-performing pairs. We used the resulting caffeine-inducible domains in engineered cytokine receptors for caffeine-inducible STAT3 signaling and in split transcription factors (caff-TFs) containing human-derived zinc-finger proteins. Heterodimerization of split transcription factors drastically enhanced their performance compared to homodimerization. We demonstrate that caff-TFs are compatible with lentiviral and retroviral delivery to Jurkat T-cells and enable inducible expression of therapeutic genes such as chimeric antigen receptors (CARs) in response to caffeine concentrations consistent with normal coffee consumption. By using the common, non-toxic molecule caffeine, and exclusively humanized protein components, these systems promise to be a safer alternative to existing systems and may be used in synthetic biology applications and for safer, more effective cell therapies.

synthetic biology↗

bioRxiv2024

Drug-controlled CAR-T cells through the regulation of cell-cell interactions

CAR T-cell therapy is constrained by on-target, off-tumor toxicities as well as cellular exhaustion due to chronic antigen exposure. CARs comprising small-molecule controlled switches can enhance both safety and therapeutic efficacy but are limited by the scarcity of non-immunogenic protein elements responsive to non-immunosuppressive, clinically approved drugs with favorable pharmacodynamics. Here, we combine rational design and library-based optimization of a protein-protein interaction (PPI) of human origin to develop venetoclax-controlled Drug-Regulated Off-switch PPI (DROP)-CARs. DROP-CARs enable dose-dependent release of the tumor-targeting scFv and consequent T-cell dissociation from the target tumor cell. Additionally, we present proof-of-concept for a dual DROP-CAR controlled by different small molecules, as well as for logic-gated synthetic receptors enabling STAT3 signaling. We demonstrate in vitro and in vivo function of DROP-CAR T cells and conclude that the approach holds promise for clinical application.

synthetic biology↗

bioRxiv2024

Targeting protein-ligand neosurfaces using a generalizable deep learning approach

Molecular recognition events between proteins drive biological processes in living systems. However, higher levels of mechanistic regulation have emerged, where protein-protein interactions are conditioned to small molecules. Here, we present a computational strategy for the design of proteins that target neosurfaces, i.e. surfaces arising from protein-ligand complexes. To do so, we leveraged a deep learning approach based on learned molecular surface representations and experimentally validated binders against three drug-bound protein complexes. Remarkably, surface fingerprints trained only on proteins can be applied to neosurfaces emerging from small molecules, serving as a powerful demonstration of generalizability that is uncommon in deep learning approaches. The designed chemically-induced protein interactions hold the potential to expand the sensing repertoire and the assembly of new synthetic pathways in engineered cells.

biochemistry↗

bioRxiv2023

Rationally designed protein bandpass filters for controlling cellular signaling with chemical inputs

Biological mechanisms that rely on signal integration and processing are fundamental for cell function. These types of capabilities are analogous to those found in electronic circuits where individual components perform operations on input signals. In electronics, bandpass filters are crucial components to narrow frequencies within a specified range and reject frequencies outside of that range. However, no generalizable protein-based components are currently available to mimic such processes in engineered biological systems, representing an unmet need in controllable modules. Here, we propose a rational design approach to create protein-based chemically responsive bandpass filters (CBP) which pass chemical concentrations within a range and reject concentrations outside of that range, showing an OFF-ON-OFF regulatory pattern. The CBPs were designed using structure-based approaches where we created a heterodimeric construct which the assembly is triggered by low concentration of a small-molecule, and this interaction is inhibited at high concentrations of the drug, effectively creating a bandpass filter. The CBPs have a multidomain architecture where we used known drug-receptors, a computationally designed protein binder and small-molecule inhibitors. Owing to the modularity of the system, each domain of the CBPs can be rationally fine-tuned to optimize its performance, including bandwidth, maximum response, cutoff concentration and fold changes. These CBPs were used to regulate cell surface receptor signaling pathways showing the capability to control cellular activities in engineered cells.

synthetic biology↗

bioRxiv2022

Rational design of chemically controlled antibodies and protein therapeutics

Protein-based therapeutics such as monoclonal antibodies and cytokines are important therapies in various pathophysiological conditions such as oncology, auto-immune disorders, and viral infections. However, the wide application of such protein therapeutics is often hindered by dose-limiting toxicities and adverse effects, namely cytokine storm syndrome, organ failure and others. Therefore, spatiotemporal control of the activities of these proteins is crucial to further expand their application. Here, we report the design and application of small molecule-controlled switchable protein therapeutics by taking advantage of a previously engineered OFF-switch system. We used Rosetta modeling suite to computationally optimize the affinity between B-cell lymphoma 2 (Bcl-2) protein and a previously developed computationally designed protein partner (LD3) to obtain a fast and efficient heterodimer disruption upon addition of a competing drug (Venetoclax). The incorporation of the engineered OFF-switch system into CTLA4, anti-HER2 antibodies or an Fc-fused IL-15 cytokine demonstrated an efficient disruption in vitro, as well as fast clearance in vivo upon addition of the competing drug Venetoclax. These results provide a proof-of-concept for the rational design of controllable biologics by introducing a drug-induced OFF-switch into existing protein-based therapeutics.

bioengineering↗

bioRxiv2021

A rational blueprint for the design of chemically-controlled protein switches

Small-molecule responsive protein switches are crucial components to control synthetic cellular activities. However, the repertoire of small-molecule protein switches is insufficient for many applications, including those in the translational spaces, where properties such as safety, immunogenicity, drug half-life, and drug side-effects are critical. Here, we present a computational protein design strategy to repurpose drug-inhibited protein-protein interactions as OFF- and ON-switches. The designed binders and drug-receptors form chemically-disruptable heterodimers (CDH) which dissociate in the presence of small molecules. To design ON-switches, we converted the CDHs into a multi-domain architecture which we refer to as activation by inhibitor release switches (AIR) that incorporate a rationally designed drug-insensitive receptor protein. CDHs and AIRs showed excellent performance as drug responsive switches to control combinations of synthetic circuits in mammalian cells. This approach effectively expands the chemical space and logic responses in living cells and provides a blueprint to develop new ON- and OFF-switches for basic and translational applications.

biochemistry↗

bioRxiv2020

A bottom-up approach for the de novo design of functional proteins

De novo protein design has enabled the creation of novel protein structures. To design novel functional proteins, state-of-the-art approaches use natural proteins or first design protein scaffolds that subsequently serve as templates for the transplantation of functional motifs. In these approaches, the templates are function-agnostic and motifs have been limited to those with regular secondary structure. Here, we present a bottom-up approach to build de novo proteins tailored to structurally complex functional motifs. We applied a bottom-up strategy to design scaffolds for four different binding motifs, including one bi-functionalized protein with two motifs. The de novo proteins were functional as biosensors to quantify epitope-specific antibody responses and as orthogonal ligands to activate a signaling pathway in engineered mammalian cells. Altogether, we present a versatile strategy for the bottom-up design of functional proteins, applicable to a wide range of functional protein design challenges.

bioengineering↗